Cala Health secures $50M to market its tremor-treating wearable

Cash register full of money
Currently, Cala is prepping for a limited release of its prescription device, with plans to serve as a direct distributor to patients. (Michael Burrell/iStock/Getty Images Plus)

To help bring its nerve-stimulating wearable to market, Cala Health collected $50 million that it also plans to use to expand its therapeutic pipeline.

The series C round saw new investments from Novartis, Baird Capital, LifeSci Venture Partners, TriVentures and others. Cala’s previous backers also returned, including Johnson & Johnson Innovation, Lux Capital, Lightstone Ventures, Action Potential Venture Capital, GV and dRx Capital, a joint investment company between Novartis and Qualcomm.

“This financing follows exciting momentum from the past year, including receiving de novo clearance from the Food and Drug Administration for our therapy for essential tremor and announcing a licensing agreement and ongoing collaboration with Partners HealthCare Innovation and its affiliate, Massachusetts General Hospital (MGH),” Cala founder and CEO Kate Rosenbluth said in a statement.


Webinar: Meet the Challenge of Complex Protein Expression

As market demand continues to rise for more potent and effective therapeutics, biologic pipelines are evolving from standard antibody formats to next-generation biologics (NGBs). In this webinar we will discuss and demonstrate application through case studies, two significant enhancements to Lonza’s GS Xceed® expression system to help address the challenges of NGBs.

Currently, Cala is prepping for a limited release of its prescription Cala Trio device for essential hand tremors, a chronic nerve disorder that can cause uncontrollable shaking. The company aims to serve as a direct distributor to patients.

RELATED: Bioelectronics developer Cala Health partners up with MGH against chronic diseases

This past March, Cala launched its collaboration with MGH and Partners HealthCare, the hospital’s intellectual property management arm, to explore the brain’s reactions to chronic pain and different forms of neural stimulation.

The end goal is to build a platform for noninvasive bioelectric treatments for multiple chronic conditions. To start, the company licensed technologies aimed at the vagus nerve, as well as stimulation that syncs up with a person’s breath to treat high blood pressure.

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.